Fractyl Health, a clinical-stage company developing treatments for obesity and type 2 diabetes, will announce its third quarter 2026 financial results and provide business updates on November 12, 2026. The company is advancing its lead product, Revita, an endoscopic therapy aimed at weight maintenance after GLP-1 treatment. Investors can join a live webcast and submit questions ahead of the call. This update is important as Fractyl moves toward potential FDA submission and commercialization of Revita.
Fractyl Health's upcoming Q3 2026 financial results provide context for health sector activity on Pluang as of Nov 06, 2026 18:31 WIB. Among 150 health-sector US stocks, 47 rose and 94 fell. Notably, TransMedics Group Inc (TMDX) gained 11.83% with 100% buy orders and a typical hold time of 26 days, contrasting with Natera Inc. (NTRA) which dropped 14.38% with 59% sell orders and a 14-day hold time, and DENTSPLY SIRONA Inc. (XRAY) which fell 10.80% and is held typically for 74 days.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
Tesla and SpaceX, Elon Musk's two largest public companies, lost a combined $457 billion in market value between November 3 and 5, 2026, following Democratic wins in Congress and key Texas races. Tesla's stock dropped nearly 14%, while SpaceX fell ov...
Arch Biopartners announced a non-brokered private placement of 1,058,823 shares at $0.85 each, raising $900,000 CAD. The funds will support onboarding U.S. clinical sites for their Phase II trial of the LSALT peptide targeting acute kidney injury rel...
